CAROLINA to Strengthen Anti-SU Guidelines

Today, BI/Lilly presented data from the CAROLINA CVOT (Tradjenta vs Glimepiride) at the ADA 2019 conference. The results demonstrated non-inferiority on 3P-MACE for linagliptin vs. glimepiride (11.8% vs. 12.0%; HR 0.98; p<0.0001) in patients with relatively early T2DM and increased CV risk. Of note, the results signaled no difference in CV safety between both groups, thereby disproving the hypothesis of increased CV risk from glimepiride usage. Recall, in February 2019, BI/Lilly announced that CAROLINA met the primary endpoint of non-inferiority on 3P-MACE. Below, FENIX provides additional thoughts on CAROLINA, potential market dynamics, and implications.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.